Core Insights - Clearmind Medicine Inc. has filed a patent application in South Korea for its proprietary compound MEAI, aimed at treating depression, thereby enhancing its global intellectual property protection [1][2][4] - MEAI is a non-hallucinogenic neuroplastogen that modulates serotonin pathways and promotes neuroplasticity, offering a new therapeutic approach for major depressive disorder, which affects over 280 million people globally [3][4] - The company has a robust intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and expand its IP protection [5][6] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, including depression and alcohol use disorder [1][5] - The company is preparing for the next stages of clinical development and commercialization of its non-hallucinogenic therapies, aiming to bring these treatments to patients worldwide [5][6]